ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CRDF vs CSBR // FREE CASH FLOW YIELD

Cardiff Oncology Inc. (NASDAQ) VS. Champions Oncology Inc. (NASDAQ) • 15-METRIC TALLY: CRDF 1 — CSBR 6
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRDF VS. CSBR) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CRDF CSBR SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 48.00% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -26.90% -8.10 CSBR /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE — -7.52% — TIE /fcf-yield <GO>
Operating Margin -60.00% -1.90% -58.10 CSBR /operating-margins <GO>
Net Profit Margin -7.70% 0.00% -7.70 CSBR /net-margins <GO>
Revenue Growth (YoY) -13.20% 4.40% -17.60 CSBR /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 2/9 -1.00 CSBR /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 38.9 46.7 -7.85 CSBR /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $70.9M $66.9M $4.0M CRDF /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CRDF REV CSBR REV CRDF GROSS % CSBR GROSS % CRDF FCF CSBR FCF
FY 2025 $593.0K $59.4M — 48.0% -$38.0M -$5.0M
FY 2024 $683.0K $56.9M — 50.1% -$37.8M $7.0M
FY 2023 $488.0K $50.2M — — -$30.9M -$6.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRDF // BETA —
CSBR // BETA —